ADC Therapeutics Licenses Proprietary Antibodies From Five Prime Therapeutics, Inc., Adds an Additional Proprietary ADC Development Program in Oncology

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LAUSANNE, Switzerland and SOUTH SAN FRANCISCO, Calif., Nov. 5, 2013 (GLOBE NEWSWIRE) -- ADC Therapeutics Sarl ('ADC Therapeutics'), a portfolio company of Auven Therapeutics and the oncology drug development company specializing in proprietary antibody drug conjugates ('ADCs'), and Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced an exclusive license agreement for human antibodies directed to an undisclosed target expressed on the surface of various types of cancers.

Help employers find you! Check out all the jobs and post your resume.

Back to news